Background/Objectives: Studies have indicated that forgoing lung shunt fraction measurement in select patients undergoing Yttrium 90 (Y90) transarterial radioembolization (TARE) may be safe without sacrificing efficacy. This study evaluated the safety and efficacy of a streamlined treatment in patients with small hepatocellular carcinoma (HCC) receiving resin-based TARE. Methods: Patients who received single-session Y90 TARE between September 2023 and May 2024 were retrospectively evaluated. Treatment response was evaluated at the 3-month follow-up using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Adverse events (AEs) ≥ Grade 3 were recorded post-procedurally at 3 months. The time from the interventional radiology clinic visit to the procedure date was compared to patients receiving the conventional TARE treatment. Results: Ten consecutive patients were treated with 12 treatments. Each treatment targeted an isolated lesion with median size of 2.5 cm (IQR: 2.1, 2.9). Two patients received two treatments (one for treatment of a separate lesion and the other for the initial incomplete targeting of the tumor). The median delivered tumor dose was 377.7 Gy (IQR: 246.5, 570.1). No patients developed ≥ Grade 3 AEs post-TARE. Complete response was achieved in 11/12 patients (92%). The conventional cohort consisted of 60 patients, all OPTN T2 treated with radiation segmentectomy with glass microspheres. Patients undergoing SSMT had a median time from clinic visit to treatment of 26.5 days (IQR: 15.3, 39) vs. 61 days (IQR: 48, 88.8) in the conventional TARE group (p< 0.001). Conclusions: Streamlined single-session resin-based Y90-TARE in patients with OPTN T2 stage HCC is feasible, efficacious, safe, and associated with reduced time to treatment.
背景/目的：研究表明，对于部分接受钇90（Y90）经动脉放射栓塞治疗的患者，省略肺分流分数测量可能在不影响疗效的前提下确保安全性。本研究旨在评估简化治疗方案对接受树脂微球Y90放射栓塞治疗的小肝细胞癌患者的安全性与有效性。方法：回顾性分析2023年9月至2024年5月期间接受单次Y90放射栓塞治疗的患者。采用改良实体瘤疗效评价标准在术后3个月随访时评估治疗反应，并记录≥3级不良事件。比较简化治疗组与传统放射栓塞治疗组从介入放射科门诊就诊至接受治疗的时间间隔。结果：共10例患者接受12次治疗，治疗靶病灶均为孤立性病灶，中位直径2.5厘米（四分位距：2.1，2.9）。其中2例患者接受两次治疗（1例因新发病灶，1例因首次肿瘤靶向不全）。中位肿瘤辐射剂量为377.7戈瑞（四分位距：246.5，570.1）。所有患者术后均未出现≥3级不良事件。11/12例患者（92%）达到完全缓解。传统治疗组60例OPTN T2分期患者均接受玻璃微球放射节段栓塞治疗。简化治疗组从就诊至治疗的中位时间为26.5天（四分位距：15.3，39），显著短于传统治疗组的61天（四分位距：48，88.8）（p<0.001）。结论：对于OPTN T2分期肝细胞癌患者，简化的单次树脂微球Y90放射栓塞治疗方案具有可行性、有效性及安全性，并能显著缩短治疗等待时间。
肿瘤(癌症)患者之家